Research map: Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis

Back to the article

Papers in this map

  1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer · Ian F. Tannock · 2004 · 5781 citations · Cited by this paper
  2. Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies · 2026 · Related
  3. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer · Oliver A. Sartor · 2021 · 2844 citations · Cited by this paper
  4. The Utility of the Comprehensive Complication Index in Demonstrating the Complication Burden and Predicting Length of Stay in Robot-Assisted Radical Prostatectomy · 2026 · Related
  5. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer · Ronald de Wit · 2019 · 685 citations · Cited by this paper
  6. Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation · 2026 · Related
  7. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial · Pirkko‐Liisa Kellokumpu‐Lehtinen · 2013 · 212 citations · Cited by this paper
  8. Exploration of the Challenges in the Management of Prostate Cancer in East Africa · 2025 · Related
  9. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population · Stephen J. Freedland · 2023 · 115 citations · Cited by this paper
  10. Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study · 2026 · Related
  11. Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management · Tivya Kulasegaran · 2024 · 71 citations · Cited by this paper
  12. Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications—A Systematic Review · 2026 · Related
  13. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update · Rohan Garje · 2025 · 63 citations · Cited by this paper
  14. Impact of Age on Outcomes in Metastatic Non–Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT) · 2026 · Related
  15. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer · Wainer Zoli · 1999 · 55 citations · Cited by this paper
  16. A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer · 2025 · Related
  17. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial · Leslie Rogers Laufman · 2001 · 54 citations · Cited by this paper
  18. Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules · 2025 · Related
  19. Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer · Edoardo Francini · 2016 · 41 citations · Cited by this paper
  20. Why Has Prostate Cancer Research Lagged Behind? Advocacy, Biology, and the Road Ahead · 2026 · Related
  21. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer—biweekly versus standard triweekly XELOX (The ORION Study) · Chu Matsuda · 2015 · 36 citations · Cited by this paper
  22. Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data · Jason Hu · 2021 · 31 citations · Cited by this paper
  23. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor · Michael Hejna · 2000 · 30 citations · Cited by this paper
  24. Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer · Stéphane Marie. Oudard · 2023 · 23 citations · Cited by this paper
  25. Gemcitabine and docetaxel in metastatic, castrate‐resistant prostate cancer · Jorge Alberto Garcia · 2010 · 19 citations · Cited by this paper
  26. Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial · Karim S. Fizazi · 2025 · 19 citations · Cited by this paper
  27. A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard) · Herbert I. Hurwitz · 2012 · 15 citations · Cited by this paper
  28. Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329 · Binu Malhotra · 2013 · 13 citations · Cited by this paper
  29. Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck · Ammar W. Sukari · 2015 · 6 citations · Cited by this paper
  30. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety · Hiroaki Tanioka · 2019 · 5 citations · Cited by this paper
  31. Real-world treatment landscape in advanced metastatic castration resistant prostate cancer. · Elizabeth Sacchi · 2024 · 1 citation · Cited by this paper
  32. Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial · Hangyu Zhang · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)